Vendor Intelligence Report: Qingdao VitaConin International Trading

Published 13 Jun 2026. 16-page investigative report on who is behind Qingdao VitaConin International Trading: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 5 Finnrick lab tests, Qingdao VitaConin International Trading has an 80% overall pass rate (4 pass / 1 fail). That headline is narrowly useful: every Finnrick sample is Tirzepatide, making VitaConin a possible but not clean Tirzepatide source, with no product-specific support for HGH, BPC-157, TB-500 or the broader catalog.

The non-lab diligence matters because VitaConin’s storefront tells a longer, more factory-like story than the dated web and registry trail can corroborate. A homepage experience claim conflicts with domain-registration, archive and copyright evidence; the listed Qingdao location reads more like a multi-tenant bonded-port office than a verified production site; and searches did not resolve a legal Chinese entity behind the English trading name.

The report also maps a sister-brand footprint: VitaConin and Vita Kangying-branded pages share sales-contact infrastructure, creating a brand-pivot problem for buyers trying to match COAs, refunds and reputation history to one accountable counterparty. Reddit warnings alleging contaminated product and refund refusal are treated cautiously because they are single-source, but they are adverse enough to affect order sizing and documentation.

The practical read is directional, not blanket condemnation: Tirzepatide has some lab support but remains verification-required, while untested catalog items should be treated as fresh-vendor risk. The full report shows how the lab view changes under stricter methodology assumptions.

Inside the full report:

  • Appendix A Finnrick laboratory breakdown and methodology-divergence charts for the single tested product
  • WHOIS/RDAP, archive and certificate-transparency exhibits for vitaconin.com
  • Homepage, About page and HGH product-page screenshots covering experience, purity and MOQ claims
  • Facebook captures tying VitaConin to Vita Kangying through a shared QQ identifier and related sales channels
  • Address analysis of the Qingdao bonded-port office location and nearby company overlaps
  • Reddit warning captures, source-confidence handling and affiliate/promotion scan results

Risk assessment

  • Corporate-history and legal-identity risk — high: Website claims “8+ Years Industry Experience,” but vitaconin.com was registered 2025-12-30 and registry searches found no direct Vitaconin entity match.
  • Tirzepatide batch-reliability risk — medium: Finnrick records 5 Tirzepatide tests with 4 pass / 1 fail and a 79.27% rating; this is a mixed product-specific signal, not a clean record.
  • Manufacturing-claim verification risk — medium: VitaConin markets as a manufacturer while the listed Qingdao address is a multi-tenant bonded-port office address shared by other companies; no factory was verified.
  • Brand-pivot / sister-brand opacity risk — medium: VitaConin and Vita Kangying properties share QQ 1219732989@qq.com and related WhatsApp infrastructure, but the relationship is not clearly disclosed to buyers.
  • Reputation and refund-dispute risk — medium: Reddit warnings from u/No-Presentation-7193 allege contaminated peptides and refund refusal; single-source and undocumented, but material for transaction sizing.